Survival Outcomes with Regorafenib and/or Trifluridine/Tipiracil Sequencing to Rechallenge with Third-Line Regimens in Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Subgroup Comparison from the ReTrITA Study.

In detail, in the cohort undergoing rechallenge therapy, we found a statistical trend towards better prognosis with R/T sequential therapy than with T/R sequence in patients with an ECOG PS = 0–1, in men, and with R monotherapy compared to T in patients with only hepatic metastases, especially in men.

also in 2,798 other papers